Journal
CA-A CANCER JOURNAL FOR CLINICIANS
Volume 62, Issue 3, Pages 147-172Publisher
WILEY
DOI: 10.3322/caac.21139
Keywords
-
Categories
Funding
- Qiagen
- Roche
- Gen-Probe, Inc
- BD
- Abbott Laboratories
- Roche Molecular Systems
- Merck, Inc
- GlaxoSmithKline (GSK), Inc.
- National Institute of Allergy and Infectious Diseases
Ask authors/readers for more resources
An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from 6 working groups, and a recent symposium cosponsored by the ACS, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology, which was attended by 25 organizations. The new screening recommendations address age-appropriate screening strategies, including the use of cytology and high-risk human papillomavirus (HPV) testing, follow-up (eg, the management of screen positives and screening intervals for screen negatives) of women after screening, the age at which to exit screening, future considerations regarding HPV testing alone as a primary screening approach, and screening strategies for women vaccinated against HPV16 and HPV18 infections. CA Cancer J Clin 2012. (C) 2012 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available